The therapeutic efficacy of bone-marrow-derived cells in patients with acute or chronic myocardial infarction has been a matter of intense debate. Three new clinical trials—the Swiss-AMI, CELLWAVE, and C-CURE studies—unfortunately do not resolve the controversy in the field of cell therapy for the damaged heart.
- Annarosa Leri
- Piero Anversa
